NPTH NeuPath Health Inc.
NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatrists, endocrinologists, gastroenterologists, general practitioners, internal medicine specialists, neurologists, neuropsychiatrists, neuropsychologists, occupational therapists, ophthalmologists, orthopedic surgeons, physiatrists, physiotherapists, psychologists, respirologists, and rheumatologists. In addition, it operates a network of healthcare clinics and related businesses. The company is headquartered in Mississauga, Canada.…
Industry Peers
Medical Care FacilitiesKey Statistics
About NeuPath Health (CVE: NPTH)
›
NeuPath Health (CVE: NPTH) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 152 employees.
The shares were at 0.4650 CAD on 20 November 2026, up 32.9% over 52 weeks. Its 52-week range is 0.3500 CAD to 0.6800 CAD: the price is 31.6% below the high and 32.9% above the low.
At a market capitalisation of 26.50M CAD, it trades at 23.3 times trailing earnings and 4.7 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.8, so NPTH is valued in line with them.
NeuPath Health reports return on equity of -3.5%, an operating margin of 2.9% and revenue up 1.2% year over year.
Its debt exceeds its cash by 8.82M CAD, a debt-to-equity ratio of 0.64. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 0.8150 CAD is 75.3% above the current price. The next earnings report is expected on 25 March 2027.